Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

C. F. Perno, R. Yarchoan, D. A. Cooney, N. R. Hartman, S. Gartner, M. Popovic, Z. Hao, T. L. Gerrard, Y. A. Wilson, D. G. Johns, S. Broder

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Because of the probable role of HIV-infected monocyte/macrophages in the pathogenesis and progression of AIDS, it is essential that antiretroviral therapy address viral replication in cells of this lineage. Several dideoxynucleosides have been shown to have potent in vitro and, in the case of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these compounds must be phosphorylated (activated) in target cells, and because monocyte/macrophages may have levels of kinases that differ from those in lymphocytes, we investigated the capacity of these drugs to suppress HIV replication in monocyte/macrophages using HIV-1/HTLV-III(Ba-L) (a monocytotropic isolate). In the present study, we observed that HTLV-III(Ba-L) replication in fresh human peripheral blood monocyte/macrophages was suppressed by each of three dideoxynucleosides: 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/macrophages, although higher concentrations of the drugs were required. We then studied the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a triphosphate moiety was somewhat decreased in monocyte/macrophages as compared with H9 T cells. On the other hand, the phosphorylation of AZT in monocyte/macrophages was markedly decreased to 25% or less of the level in T cells. However, when we examined the level of the normal endogenous 2'-deoxynucleoside triphosphate pools, which compete with 2',3'-dideoxynucleoside triphosphate for viral reverse transcriptase, we found that the level of 2'-deoxycytidine-triphosphate (dCTP) was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP) was only a small fraction of that found in T cell lines. These results suggest that the ratio of dideoxynucleoside triphosphate to normal deoxynucleoside triphosphate is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV target cells, and the lower levels of dTTP may account for the antiretroviral activity of AZT in the face of inefficient phosphorylation of this compound.

Original languageEnglish
Pages (from-to)1111-1125
Number of pages15
JournalJournal of Experimental Medicine
Volume168
Issue number3
Publication statusPublished - 1988

Fingerprint

Dideoxynucleosides
Zidovudine
HIV-1
Monocytes
Zalcitabine
Macrophages
HIV
Phosphorylation
T-Lymphocytes
Dideoxyadenosine
RNA-Directed DNA Polymerase
Cell Lineage
Pharmaceutical Preparations
Thymidine
Antiviral Agents
Acquired Immunodeficiency Syndrome
Phosphotransferases
triphosphoric acid
Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Immunology

Cite this

Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. / Perno, C. F.; Yarchoan, R.; Cooney, D. A.; Hartman, N. R.; Gartner, S.; Popovic, M.; Hao, Z.; Gerrard, T. L.; Wilson, Y. A.; Johns, D. G.; Broder, S.

In: Journal of Experimental Medicine, Vol. 168, No. 3, 1988, p. 1111-1125.

Research output: Contribution to journalArticle

Perno, CF, Yarchoan, R, Cooney, DA, Hartman, NR, Gartner, S, Popovic, M, Hao, Z, Gerrard, TL, Wilson, YA, Johns, DG & Broder, S 1988, 'Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides', Journal of Experimental Medicine, vol. 168, no. 3, pp. 1111-1125.
Perno, C. F. ; Yarchoan, R. ; Cooney, D. A. ; Hartman, N. R. ; Gartner, S. ; Popovic, M. ; Hao, Z. ; Gerrard, T. L. ; Wilson, Y. A. ; Johns, D. G. ; Broder, S. / Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. In: Journal of Experimental Medicine. 1988 ; Vol. 168, No. 3. pp. 1111-1125.
@article{1f0177f16825423ba6de46b765414c28,
title = "Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides",
abstract = "Because of the probable role of HIV-infected monocyte/macrophages in the pathogenesis and progression of AIDS, it is essential that antiretroviral therapy address viral replication in cells of this lineage. Several dideoxynucleosides have been shown to have potent in vitro and, in the case of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these compounds must be phosphorylated (activated) in target cells, and because monocyte/macrophages may have levels of kinases that differ from those in lymphocytes, we investigated the capacity of these drugs to suppress HIV replication in monocyte/macrophages using HIV-1/HTLV-III(Ba-L) (a monocytotropic isolate). In the present study, we observed that HTLV-III(Ba-L) replication in fresh human peripheral blood monocyte/macrophages was suppressed by each of three dideoxynucleosides: 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/macrophages, although higher concentrations of the drugs were required. We then studied the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a triphosphate moiety was somewhat decreased in monocyte/macrophages as compared with H9 T cells. On the other hand, the phosphorylation of AZT in monocyte/macrophages was markedly decreased to 25{\%} or less of the level in T cells. However, when we examined the level of the normal endogenous 2'-deoxynucleoside triphosphate pools, which compete with 2',3'-dideoxynucleoside triphosphate for viral reverse transcriptase, we found that the level of 2'-deoxycytidine-triphosphate (dCTP) was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP) was only a small fraction of that found in T cell lines. These results suggest that the ratio of dideoxynucleoside triphosphate to normal deoxynucleoside triphosphate is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV target cells, and the lower levels of dTTP may account for the antiretroviral activity of AZT in the face of inefficient phosphorylation of this compound.",
author = "Perno, {C. F.} and R. Yarchoan and Cooney, {D. A.} and Hartman, {N. R.} and S. Gartner and M. Popovic and Z. Hao and Gerrard, {T. L.} and Wilson, {Y. A.} and Johns, {D. G.} and S. Broder",
year = "1988",
language = "English",
volume = "168",
pages = "1111--1125",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-L)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

AU - Perno, C. F.

AU - Yarchoan, R.

AU - Cooney, D. A.

AU - Hartman, N. R.

AU - Gartner, S.

AU - Popovic, M.

AU - Hao, Z.

AU - Gerrard, T. L.

AU - Wilson, Y. A.

AU - Johns, D. G.

AU - Broder, S.

PY - 1988

Y1 - 1988

N2 - Because of the probable role of HIV-infected monocyte/macrophages in the pathogenesis and progression of AIDS, it is essential that antiretroviral therapy address viral replication in cells of this lineage. Several dideoxynucleosides have been shown to have potent in vitro and, in the case of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these compounds must be phosphorylated (activated) in target cells, and because monocyte/macrophages may have levels of kinases that differ from those in lymphocytes, we investigated the capacity of these drugs to suppress HIV replication in monocyte/macrophages using HIV-1/HTLV-III(Ba-L) (a monocytotropic isolate). In the present study, we observed that HTLV-III(Ba-L) replication in fresh human peripheral blood monocyte/macrophages was suppressed by each of three dideoxynucleosides: 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/macrophages, although higher concentrations of the drugs were required. We then studied the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a triphosphate moiety was somewhat decreased in monocyte/macrophages as compared with H9 T cells. On the other hand, the phosphorylation of AZT in monocyte/macrophages was markedly decreased to 25% or less of the level in T cells. However, when we examined the level of the normal endogenous 2'-deoxynucleoside triphosphate pools, which compete with 2',3'-dideoxynucleoside triphosphate for viral reverse transcriptase, we found that the level of 2'-deoxycytidine-triphosphate (dCTP) was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP) was only a small fraction of that found in T cell lines. These results suggest that the ratio of dideoxynucleoside triphosphate to normal deoxynucleoside triphosphate is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV target cells, and the lower levels of dTTP may account for the antiretroviral activity of AZT in the face of inefficient phosphorylation of this compound.

AB - Because of the probable role of HIV-infected monocyte/macrophages in the pathogenesis and progression of AIDS, it is essential that antiretroviral therapy address viral replication in cells of this lineage. Several dideoxynucleosides have been shown to have potent in vitro and, in the case of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these compounds must be phosphorylated (activated) in target cells, and because monocyte/macrophages may have levels of kinases that differ from those in lymphocytes, we investigated the capacity of these drugs to suppress HIV replication in monocyte/macrophages using HIV-1/HTLV-III(Ba-L) (a monocytotropic isolate). In the present study, we observed that HTLV-III(Ba-L) replication in fresh human peripheral blood monocyte/macrophages was suppressed by each of three dideoxynucleosides: 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/macrophages, although higher concentrations of the drugs were required. We then studied the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a triphosphate moiety was somewhat decreased in monocyte/macrophages as compared with H9 T cells. On the other hand, the phosphorylation of AZT in monocyte/macrophages was markedly decreased to 25% or less of the level in T cells. However, when we examined the level of the normal endogenous 2'-deoxynucleoside triphosphate pools, which compete with 2',3'-dideoxynucleoside triphosphate for viral reverse transcriptase, we found that the level of 2'-deoxycytidine-triphosphate (dCTP) was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP) was only a small fraction of that found in T cell lines. These results suggest that the ratio of dideoxynucleoside triphosphate to normal deoxynucleoside triphosphate is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV target cells, and the lower levels of dTTP may account for the antiretroviral activity of AZT in the face of inefficient phosphorylation of this compound.

UR - http://www.scopus.com/inward/record.url?scp=0023785829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023785829&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 1111

EP - 1125

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -